deltatrials
Terminated INTERVENTIONAL NCT01604889

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Sponsor: Incyte Corporation

Conditions Melanoma
Interventions Epacadostat ipilimumab
Updated 17 times since 2017 Last updated: Apr 15, 2026 Started: Mar 29, 2012 Primary completion: Dec 27, 2016 Completion: Jan 20, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Melanoma trials with similar outcome

Browse all Melanoma trials

This observational or N/A phase trial investigates Melanoma and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 17 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Nov 2020 · 19 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2026 · 20 months · monthly snapshotApr 21, 2026 – present · 3 months · daily API

Change History

17 versions recorded

  1. Apr 21, 2026 — Present [daily]

    Terminated

    Phase: PHASE1/PHASE2 → None

  2. Sep 2024 — Apr 2026 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Dec 2021 — Apr 2022 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  3. Apr 2019 — Nov 2020 [monthly]

    Terminated PHASE1_PHASE2

  4. Jun 2018 — Apr 2019 [monthly]

    Terminated PHASE1_PHASE2

  5. May 2018 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

  6. Feb 2018 — May 2018 [monthly]

    Terminated PHASE1_PHASE2

  7. Aug 2017 — Feb 2018 [monthly]

    Terminated PHASE1_PHASE2

  8. Jun 2017 — Aug 2017 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  9. Apr 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Mar 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The study design included an open-label, dose escalation phase followed by a blinded, randomized phase, which combined epacadostat (an oral IDO1 inhibitor) with an approved therapy and compared to approved therapy plus placebo in metastatic melanoma patients. Only Phase 1 of the study, dose escalation phase, was conducted. The study was terminated due to a business decision.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations